6月10日9:30，仁醫醫療三人團隊前往哥廷根大學醫療中心，拜訪病理科主任、哥廷根癌癥中心副主任、國際病理學學會德國分會主席Str?bel 教授，并就中德在精準病理診斷領域的合作進行了深入交流。Str?bel教授是德國病理學界的重要人物，曾參與主筆世界衛生組織（WHO）2004、2015與2021年版腫瘤分類標準中有關肺、胸膜、胸腺和心臟腫瘤的病理學和遺傳學章節。作為2025年德國病理學年會主席，他將于6月12日至14日在萊比錫主持這一年度學術盛會。哥廷根大學創立于1737年，是德國最古老、學術氛圍最濃厚的大學之一，其附屬醫療中心是下薩克森州南部唯一被認證的最高等級醫療服務提供者，在德國醫學體系中占據核心地位。其病理科每年處理約4.5萬個病例，制作評估約20萬份組織學樣本，診斷流程已全面實現電子化。科研方面設有5個由教授領導的研究團隊，涵蓋組織病理學、分子病理與人工智能等方向，科研架構系統完善、交叉融合。2020年，Str?bel教授與西門子聯合發起“Cancer Scout”人工智能研究項目，獲得德國聯邦教育與研究部（BMBF）資助，總金額高達960萬歐元。該項目致力于開發一種基于AI的“數字活檢”工具，利用醫生在日常診斷中最常用的常規病理切片圖像，預測患者腫瘤是否存在關鍵的分子突變，從而在無需額外分子檢測的情況下，輔助判斷病人是否適合靶向治療。項目構建了一個大型、跨中心的圖像-分子數據庫，收集成千上萬例肺癌、結直腸癌等實體瘤的樣本，通過深度學習模型識別圖像中極其細微的細胞形態與分子突變之間的潛在關聯。這項技術有望在降低診斷成本、提升診斷效率的同時，為德國每年近50萬例新發癌癥患者提供更便捷、普及的精準醫療方案。Str?bel教授表示，自己早在1993年就曾訪問中國武漢，對中國醫療體系的發展始終保持高度興趣。他即將與深圳知名大學附屬醫院開啟深度合作，同時也非常期待與仁醫醫療團隊的后續合作，認為這將為他帶來一次全新的對中國的理解與體驗。

At 9:30 am on June 10, the team of three from Gloryren went to the University Medical Center G?ttingen and visited Prof. Str?bel, the Director of the Institute of Pathology, Deputy Spokesperson of the G?ttingen Comprehensive Cancer Center (G-CCC), and President of the German Division of the International Academy of Pathology(IAP). They engaged in in-depth discussions regarding Sino-German cooperation in the field of precision pathological diagnosis. Prof. Str?bel is a prominent figure in the field of pathology in Germany. He has co-authored numerous chapters of 2004, 2015, and 2021 editions of the World Health Organization (WHO) Classification of Tumors Volume on “Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart”. As the President of the Annual Meeting of the German Society of Pathology in 2025, he will preside over this annual academic event in Leipzig from June 12 to 14. Founded in 1737, the University of G?ttingen is one of Germany's oldest and most academically renowned institutions. Its affiliated medical center serves as the only certified highest-level healthcare provider in southern Lower Saxony, playing a central role in Germany's medical system. The Institute of Pathology handles approximately 45,000 cases annually, preparing and evaluating around 200,000 histological samples, with fully digitized diagnostic workflows. In research, it has five professor-led teams focusing on histopathology, molecular pathology, and artificial intelligence, featuring an integrated and interdisciplinary research framework. In 2020, Prof. Str?bel co-initiated the "Cancer Scout" AI-related research project with Siemens, receiving a grant of €9.6 million from the German Federal Ministry of Education and Research (BMBF). This project aims to develop an AI-based "digital biopsy" tool that analyzes the histological images—the most common diagnostic resource—to predict key molecular changes in tumors, thereby guiding targeted therapy decisions without additional molecular testing. The project has established a large-scale, multi-center image-molecular database, which contains thousands of samples from solid tumor cases, including lung cancer and colorectal cancer. Through deep learning algorithms, it identifies subtle correlations between cellular morphology and molecular alterations. This technology promises to reduce diagnostic costs, improve efficiency, and provide more accessible precision medicine for nearly 500,000 new cancer patients in Germany each year. Prof. Str?bel shared that he first visited Wuhan, China as early as 1993 and has since maintained a keen interest in the development of China’s healthcare system. He is set to launch a comprehensive collaboration with a prominent university-affiliated hospital in Shenzhen and has showed great interest in the future cooperation with the team of Gloryren, which will offer fresh perspectives to see China.